Clinical Trial Detail

NCT ID NCT03786783
Title Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

ganglioneuroblastoma

neuroblastoma

Therapies

Isotretinoin

Cyclophosphamide + Thiotepa

Cisplatin + Dinutuximab + Etoposide + Sargramostim

Cyclophosphamide + Dinutuximab + Doxorubicin + Sargramostim + Vincristine Sulfate

Dexrazoxane

Cyclophosphamide + Topotecan

Dinutuximab + Isotretinoin + Sargramostim

Carboplatin + Etoposide + Melphalan

Age Groups: child adult

No variant requirements are available.